Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Retroviral cell targeting vectors.

C J Buchholz¹, J Stitz, K Cichutek

¹Medizinische Biotechnologie, Paul-Ehrlich-Institut, Paul-Ehrlich-Strasse 51-59, 63225 Langen, Germany. bucch@pei.de

Current Opinion in Molecular Therapeutics

|March 16, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

HIV-Gag VLP-based vaccine purification at manufacturing scale: Combination of counterflow centrifugation and nuclease treatment as a key to DNA depletion.

New biotechnology·2026

Same author

Optimizing nuclease treatment to enhance anion exchange chromatography of HIV-derived virus-like particles.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2025

Same author

Substantially improved gene transfer to interneurons with second-generation glutamate receptor-targeted DART-AAV vectors.

Journal of neuroscience methods·2023

Same author

AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma.

Oncoimmunology·2022

Same author

Prototype tests of vertical and torsional alignment nulling for screening vestibular function.

Journal of vestibular research : equilibrium & orientation·2017

Same author

Holo-APP and G-protein-mediated signaling are required for sAPPα-induced activation of the Akt survival pathway.

Cell death & disease·2014

Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011

Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010

Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010

Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010

Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010

Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010

See all related articles

Developing targeted retroviral vectors is crucial for gene therapy. Strategies involve modifying envelope proteins to direct vectors to specific human cells for in vivo trials.

Area of Science:

Gene Therapy
Retroviral Vectors
Molecular Biology

Background:

Cell targeting vectors are essential for successful in vivo gene therapy.
Retroviral vectors are commonly used but often lack specificity.

Purpose of the Study:

To review strategies for genetically modifying retroviral vector envelope (Env) proteins.
To enhance the targeting of retroviral vectors to specific human cell types.

Main Methods:

Genetic modification of retroviral envelope (Env) proteins.
Substitution of complete Env proteins.
Incorporation of new receptor binding domains into Env proteins.

Main Results:

Developed strategies alter vector host range for specific human cell targeting.

Related Experiment Videos

Achieved tissue-specificity for vectors with broad natural tropism.

Identified efficient targeting vectors with clinical trial potential.

Conclusions:

Genetic modification of Env proteins offers viable strategies for targeted gene delivery.
Targeted retroviral vectors show promise for future clinical applications in gene therapy.